UK Code: More Complaints From Companies In 1996

19 August 1997

The UK Prescription Medicines Code of Practice Authority received 102complaints in 1996, compared with 104 in 1995. 42 of 1996's complaints came from health professionals and 48 from other companies, making it the first year in which the number of inter-company complaints has exceeded those received from health professionals, says the Authority's report for 1996.

There is no apparent reason for this, it says, and "it will be interesting to see whether it will prove to be an exception or the beginning of a new trend." In the first six months of 1997, 66 complaints were received, of which 33 came from health professionals and 20 from companies.

The Code of Practice Panel made 208 rulings in 1996. Of these, 165 (79%) were accepted by the complainants and respondents, 32 (15%) were unsuccessfullly appealed to the Code of Practice Appeal Board and 11 (5%) were successfully appealed. The average time taken to deal with complaints fell slightly, from eight weeks to a little over seven weeks, and the Authority aims to reduce this further. The average time taken to complete cases which went to appeal rose from 15 weeks in 1995 to nearly 16 weeks, due to one case which took many months to resolve.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight